Kardia 12L and KAI 12L

by AliveCor  · Based in United States → — The easiest way to acquire an accurate 12-lead ECG.
Cardiology Emergency Medicine Internal Medicine

$2295
Regulatory Status Disclosed

Overview

Kardia 12L and KAI 12L are an FDA-cleared, AI-powered, pocket-sized 12-lead ECG system designed for healthcare professionals. The Kardia 12L system simplifies 12-lead ECG acquisition with a single-cable design and five electrode placements, making it easier and faster to use than traditional 12-lead ECG machines. The accompanying KAI 12L AI technology, trained on over 1.75 million ECGs, can detect up to 39 cardiac determinations, including acute myocardial infarction (MI) and common ischemias, as well as various arrhythmias and morphology determinations. This system aims to expand access to high-quality 12-lead ECGs across diverse care settings, including primary and urgent care offices, employer clinics, and rural venues.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Handheld, portable 12-lead ECG system
  • Single-cable design with 5 electrode placements
  • AI-powered analysis (KAI 12L) for up to 39 cardiac determinations
  • Detection of acute myocardial infarction (MI) and common ischemias
  • Detection of various arrhythmias and morphology determinations (e.g., Short PR Interval, Atrial Bigeminy, Ventricular Bigeminy, Left Axis Deviation, Right Axis Deviation)
  • KardiaStation app for streamlined ECG acquisition and display
  • KardiaPro web portal for secure patient ECG management and review
  • Bluetooth connectivity to compatible smart devices (iOS and Android)
  • Clinically validated performance comparable to standard 12-lead ECGs
  • Unlimited cloud-based data backup

Use Cases

  • Point-of-care cardiac assessment in various clinical settings
  • Rapid detection of life-threatening cardiac conditions
  • Expanding access to 12-lead ECGs in under-resourced or rural venues
  • Simplifying ECG acquisition for healthcare professionals with infrequent ECG experience
  • Monitoring patients for a wide range of cardiac findings
  • Supporting faster clinical decision-making

What Physicians Need to Know

ECG/EKG Analysis Capability
Kardia 12L is an FDA-cleared, AI-powered, handheld 12-lead resting ECG system that acquires four standard diagnostic-bandwidth leads, derives four, and synthesizes four additional leads for a complete 12-lead recording. The KAI 12L AI technology, trained on over 1.75 million ECGs, can detect 39 cardiac determinations, including 16 arrhythmias and 23 morphologies. It offers two analysis modes: Asymptomatic (optimized for high specificity) and Symptomatic (optimized for high sensitivity).
Arrhythmia Detection Accuracy
The KAI 12L AI can identify major rhythm types including AFib, atrial flutter, 1st degree AV block, and various tachycardias. It also detects Short PR Interval, Atrial Bigeminy, Ventricular Bigeminy, Left Axis Deviation (LAD), and Right Axis Deviation (RAD). The symptomatic mode utilizes lower thresholds (0.7 probability) to maximize sensitivity for AFib detection. The system has identified over 4,000 instances of myocardial infarction and ischemia.
Heart Failure Risk Prediction
Specific heart failure risk prediction is not explicitly detailed as a feature for Kardia 12L or KAI 12L. The focus is on detection of various cardiac conditions and arrhythmias.
Coronary Artery Assessment
KAI 12L can detect serious conditions like acute myocardial infarction (MI) and the most common types of cardiac ischemia.
Cardiac Monitoring Integration
The Kardia 12L system works with the KardiaStation app for recording, displaying, and uploading ECG data. Data can be managed and reviewed securely through the KardiaPro Portal. The KAI 12L AI can seamlessly integrate with compatible devices. AliveCor offers an enterprise platform with API and SDK solutions for third-party providers to integrate and manage patient ECG data.
AHA/ACC Guideline Alignment
The Kardia 12L ECG accuracy conforms to IEC 60601-2-25:2011 standards for the basic safety and essential performance of electrocardiographs. A study showed that the Kardia 12L ECG System performs comparably to a standard hospital-grade ECG for detecting common morphological cardiac abnormalities, including heart attack.
Real-Time Alert Capability
The KardiaStation app guides the ECG recording process and automatically generates a complete 12-lead tracing. The AI provides FDA-cleared determinations to support clinical decision-making at the point of care. While not explicitly stated as 'real-time alerts' in the traditional sense, the rapid analysis and report generation support faster clinical action.
Physician Tip

Kardia 12L offers a portable and simplified approach to acquiring 12-lead ECGs, making it suitable for various care settings beyond traditional cardiology offices, such as primary care, urgent care, and home health. The dual analysis modes (Asymptomatic and Symptomatic) allow for tailored interpretation based on patient presentation. The reduced leadset and single-cable design simplify acquisition and reduce patient discomfort, potentially increasing patient compliance and workflow efficiency. However, remember that synthesized leads are for informational purposes only and not for primary diagnostic decision-making. Always integrate the AI-powered analysis with clinical history, symptoms, and other diagnostic tests. The device requires activation with a valid National Provider Identifier (NPI) number and the automated analysis should be reviewed by a qualified healthcare professional.

KAI 12L is seamlessly integrated into the Kardia 12L system and the KardiaStation app. AliveCor provides an enterprise platform with API and SDK solutions, enabling third-party providers to integrate ECG monitoring capabilities and patient ECG data into their own systems. This includes features for EHR integration, importing patient ECGs in PDF or raw time series formats, and managing patient data in the AliveCor Cloud. Webhook notifications can alert integrated systems when new ECGs are available. The KardiaStation app is compatible with various iOS and Android devices.

Details

Category Cardiology AI, Lab & Diagnostics, Wearables & Remote Monitoring (RPM)
Pricing $2295 — $2295 for Kardia 12L system; Annual licensing fee after initial 3-year period
DeploymentMobile device application with hardware
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated

Kardia 12L is an FDA 510(k) cleared 12-lead resting ECG system. KAI 12L AI technology has received FDA clearance for up to 39 cardiac determinations, including acute myocardial infarction and common ischemias.

Integrations
EHR Not specified
Specialties Cardiology, Emergency Medicine, Internal Medicine

What the Web Says

The AliveCor Kardia 12L and KAI 12L system is a prescription-only, portable 12-lead ECG device designed for healthcare professionals, aiming to bridge the gap between traditional ECG machines and consumer devices. It utilizes a simplified 5-electrode setup and AI-powered software (KAI 12L) to detect 39 FDA-cleared cardiac determinations, including acute myocardial infarction and common types of cardiac ischemia. Physicians and tech reviewers generally praise its portability, ease of use, and diagnostic accuracy, often comparing its performance favorably to hospital-grade ECGs for detecting major morphological abnormalities. The system is seen as a significant advancement for remote cardiac care and improving efficiency in various clinical settings.

Overall: Positive

Strengths

  • Highly portable and lightweight, fitting in a pocket.
  • Simplifies ECG acquisition with a single cable and 5 electrodes, reducing setup time and patient disrobing.
  • AI-powered (KAI 12L) for instant interpretation and detection of 39 FDA-cleared cardiac conditions, including acute MI and ischemia.
  • Performs comparably to standard hospital-grade 12-lead ECGs for detecting major morphological cardiac abnormalities.
  • Integrates with KardiaStation app for high-resolution displays, dual-mode analysis (Symptomatic/Asymptomatic), and efficient data management.
  • Enhances access to 12-lead ECG data in various care settings, including primary care, urgent care, and remote locations.

Limitations

  • Synthesized leads are for informational purposes and not for primary diagnostic decision-making.
  • Some Reddit users express concern about consumer devices creating anxiety without clinical context, though this is often in reference to other Kardia devices.
  • One Reddit user reported difficulty with the on-off switch of a KardiaMobile Card, which may or may not apply to the 12L.
  • Some ambiguous feedback regarding product quality, price, and value for money for Kardia products in general.

Based on reviews from: MedGrade, Kardia (kardiamobile.com), PR Newswire, Cardiac Rhythm News, Holistic Heart Centers, YouTube, Reddit, Best Buy, Walmart, Trustpilot

Last updated: 2026-07-27

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Kardia 12L and KAI 12L

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Breaking News u00b7 Regulatory
FDA Clears New Cardiac Determinations for Kardia 12L ECG System
AliveCor received FDA clearance for the next generation of KAI 12L, the AI powering the Kardia 12L ECG System, to detect five additional cardiac determinations, bringing the total to 39. This expansion enhances the diagnostic breadth of the world's first AI-powered, handheld 12-lead ECG system.
2026-02
AliveCor
AliveCor Announces FDA Clearance of New Cardiac Determinations for Kardia 12L ECG System, Bringing Total to 39
AliveCor announced FDA clearance for the next generation of KAI 12L, enabling the Kardia 12L ECG System to detect five new cardiac determinations, totaling 39. These new detections include rhythm modifiers and axis-related morphology determinations.
2026-01
Medical Product Outsourcing
CE Mark Awarded to AliveCor's AI-Powered Kardia 12L Electrocardiogram System
AliveCor received CE Mark certification for its Kardia 12L ECG System, an AI-powered, portable 12-lead ECG system for healthcare professionals. The system, powered by KAI 12L, detects 35 cardiac determinations, including acute myocardial infarction and common types of cardiac ischemia.
2026-06
TNW
AliveCor's Kardia 12L is now CE marked - TNW
AliveCor's Kardia 12L, a pocket-sized AI ECG system, has received CE Mark for launch in France, Germany, Italy, Spain, and the UK. The CE-marked version detects 35 cardiac determinations, while the FDA-cleared version detects 39.
2026-04
PR Newswire
AliveCor Launches AI-Powered Kardia 12L in Europe: The World's First Handheld 12-Lead ECG with a Unique Single-Cable Design
AliveCor announced it has received CE Mark for the Kardia 12L ECG System powered by KAI 12L AI technology, enabling faster, easier detection of 35 cardiac determinations. This launch aims to improve access to high-quality cardiac care in the EU.
2026-04
Medical Device Network
AliveCor secures FDA approval for Kardia 12L ECG System - Medical Device Network
AliveCor received FDA approval for the next generation of its KAI 12L AI, powering the Kardia 12L ECG System, to detect a total of 39 cardiac determinations. The system has seen increasing acceptance across the US and expanded into other countries.
2026-01
Cardiac Rhythm News
AliveCor launches AI-powered 12-lead ECG system in Europe - Cardiac Rhythm News
AliveCor announced CE mark for the Kardia 12L ECG system, an AI-powered, portable 12-lead ECG system for healthcare professionals. The system enables faster, easier detection of 35 cardiac determinations, including acute myocardial infarction.
2026-04
HLTH
AliveCor Secures FDA Clearance for Expanded Cardiac Determinations in Kardia 12L ECG System - HLTH
AliveCor announced FDA clearance for the next generation of KAI 12L, adding five new cardiac determinations to the Kardia 12L ECG System, bringing the total to 39. The system has been adopted by over 250 clinical practices and identified more than 4,000 cases of myocardial infarction and ischemia.
2026-01

Videos

Product demos, reviews, and walkthroughs for Kardia 12L and KAI 12L.

View all on YouTube

Frequently Asked Questions

Kardia 12L refers to AliveCor's 12-lead ECG acquisition device, while KAI 12L (Kardia AI 12L) represents the artificial intelligence algorithms applied to the 12-lead ECG data. Kardia 12L integrates by providing a portable, clinical-grade 12-lead ECG, and KAI 12L algorithms then analyze this data to provide AI-driven insights, which can be incorporated into existing EMR systems for physician review and decision-making.
KAI 12L offers AI-driven insights such as detection of certain arrhythmias, myocardial infarction, and other cardiac conditions. While specific diagnostic accuracy varies by algorithm and condition, studies have shown KAI 12L to have high sensitivity and specificity for certain detections, often augmenting or flagging potential issues for physician review rather than replacing traditional interpretation.
KAI 12L, as a medical AI device, requires appropriate regulatory clearances, such as FDA clearance in the United States, for its intended use. Physicians must ensure that the device and its associated AI algorithms are used in compliance with these regulations, and that all patient data handled by the system adheres to HIPAA and other relevant data privacy laws.
Like all AI, KAI 12L's algorithms may have limitations, such as reduced accuracy in certain patient populations, with specific ECG morphologies, or in the presence of significant artifact. Physicians should be aware of these potential biases and limitations, using the AI insights as a tool to support their clinical judgment rather than as a definitive diagnosis.
Alternatives to Kardia 12L and KAI 12L include other portable 12-lead ECG devices and various AI-powered ECG analysis platforms from different manufacturers. These alternatives may offer varying features, such as different AI algorithms for specific conditions, integration capabilities, and levels of portability, requiring physicians to evaluate them based on their specific clinical needs and preferences.
The pricing model for Kardia 12L typically involves an upfront cost for the device itself, while KAI 12L's AI analysis may be offered through a subscription service or per-use fee. Physicians should investigate potential reimbursement pathways for both the ECG acquisition and the AI-driven interpretation, as these can vary by payer and region.
KAI 12L is designed with robust data security measures, including encryption for data transmission and secure storage protocols, to protect patient privacy. It adheres to industry standards and regulatory requirements like HIPAA to ensure that sensitive ECG data is handled confidentially and securely throughout its lifecycle.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

More from AliveCor

AliveCor QT Service
AliveCor
Cardiology AI
A cloud-based Software as a Medical Device (SaMD) that provides instant, accurate QT and QTc interval measurements from AliveCor 6-Lead ECGs, enabling healthcare professionals to assess cardiac safety and inform medication prescribing decisions.
Corvair
AliveCor
Cardiology AI
Corvair by AliveCor is an FDA-cleared AI ECG analysis system that assists healthcare professionals in interpreting resting diagnostic ECGs with 35 cardiac determinations.
Impala
AliveCor
Cardiology AI
AliveCor's 'Impala' (FDA K232035) is a portable, AI-powered 12-Lead ECG device for healthcare professionals, not a physician directory tool. AliveCor specializes in cardiac monitoring solutions.
KardiaAI
AliveCor
Cardiology AI
KardiaAI by AliveCor is an FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia.

View company profile →

Suggest an Edit → | Last Verified: 2026-07-26 | First Added: 2026-07-26

Investors who backed Kardia 12L and KAI 12L

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.